![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
"Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company." Modern Rheumatology, 25(3), pp. 493–494
Conflict of interest
Pfizer (unlimited research fund of < 5,000 US dollars), Tanabe-Mitsubishi (speeking fee of < 12,000 US dollars, unlimited research fund < 30,000 US dollars), Astellas (unlimited research fund of < 25,000 US dollars), Ono Pharm (unlimited research fund < 20,000 US dollars), and Jannsen (speeking fee of < 3,000 US dollars)